Duration of trastuzumab for HER2-positive breast cancer

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 678-679

  Montemurro, Filippo ^a   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER RECURRENCE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; NOTE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 84879780511     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70273-0     Document Type: Note

References (11)

1. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012, 4. CD006243.
2. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 1 year versus 2 years of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (in press).
3. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013, the PHARE trial investigators, published online June 11. http://dx.doi.org/10.1016/S1470-2045(13)70225-0.
4. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. TCGAT.
5. Montemurro F, Rossi V, Cossu RM, et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012, 118:17-26.
6. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
7. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
8. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, 13:135-144.
9. Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013, 31:1726-1731.
10. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
11. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.